January 30, 2025 7:50am
After downdrafts usually come upside, some optimism should be set to expand
Pre-open Indications: 1 Sell into Strength and 5 Positive
Can expectation be a component of reality?
Earnings dates: MRNA and SAGE <in the Bottom Line>
Never leave an investor uninform
Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!
Markets closed for Lunar New Year holidays include Chinese, Taiwan, South Korea, Vietnam, Hong Kong, and Singapore.
Wednesday’s night’s … RegMed Investors (RMi) Closing Bell: a little more of the same … https://www.regmedinvestors.com/articles/13785
Thursday; the pre-open Dow futures are DOWN -0.06% or (-28 points), the S&P futures are UP +0.23% or (+13 points) and the Nasdaq futures are UP +0.42% or (+90 points)
- Futures rose on Thursday, 1/30/25,
- European stock markets were higher,
- Australian and Japanese stocks extend gains from the previous session.
Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies
The S&P 500 slid, the Nasdaq lost 0.51% while the Dow shed 0.31%, on Wednesday after the Fed left interest rates unchanged.
By the by, Fed chair Powell’s statement did not include that inflation “has made progress toward” the Fed’s 2% inflation goal.
Economic Data Docket: Initial jobless claims, week ending Jan. 18 (217,000 previously); Kansas City Fed. Manufacturing Activity, January (-4 prior)
Q1/25: January – 2 holidays, 1 market close, 9 negative and 9 positive closes
- Q4/24: December 1 holiday, 15 negative and 5 positive closes
- November 10 negative and 9 positive closes
- October: 8 positive and 15 negative closes
Companies in my headlights – It’s your decision; I provide ideas and context
I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
Sell into Strength:
Mesoblast (MESO) closed up +$1.23 after Tuesday’s +$0.44 with a positive +$0.02 or +0.10% aftermarket
Positive Indications:
Alnylam Pharmaceuticals (ALNY -$5.20 after Tuesday’s +$2.77 and Monday’s -$2.03 with a positive +$2.00 pre-market
Blueprint Medicine (BPMC) closed up +$0.15 after Tuesday’s +$0.59 and Monday’s -$1.03 with a positive +1.18 or +1.03% pre-open
Moderna (MRNA) closed down -$4.22 after Tuesday’s +$3.29 with a positive +$0.43 or +1.06% pre-open
Solid Biosciences (SLDB) closed up +$0.05 after Tuesday’s +$0.14 with a positive +$0.07 or +2.10% pre-open
uniQure NV (QURE) closed down -$0.08 after Tuesday’s-$0.48 with a positive +$1.03 or +6.76% pre-open
The BOTTOM LINE: Reiterating, “risk versus uncertainty – which is worst?”
The Nasdaq leads the charge for stocks rebounding from Monday's tech sell-off, the index closing Tuesday's session by over 2% higher.
January ‘25 recap:
- 1/29 – Wednesday ended with a negative close at the close of 9 incliner, 24 decliners and 2 flats
- 1/28 – Tuesday ended with a negative close at the close of 14 incliner, 17 decliners and 4 flats
- 1/27 – Monday ended with a negative close at the close of 12 incliner, 21 decliners and 2 flats
- 1/24 – Friday ended with a negative close at the close of 12 incliner, 22 decliners and 1 flat
- 1/23 – Thursday ended with a positive close at the close of 26 incliner, 4 decliners and 5 flats
- 1/22 - Wednesday ended with a positive close at the close of 18 incliner, 14 decliners and 3 flats
- 1/21 - Tuesday advance/decline line ended with a positive close at the close of 28 incliner, 6 decliners and 1 flat
- 1/20 – Inauguration Day, markets were closed
What could 2025 have in store for the capital access space as Partners are the gift of life!
- "You'll see a number of cell and gene therapy comandantes drive for secondaries – they’re desperate for cash, but I do think a lot of cell and gene therapy sector companies NEED to be focused on what is driving their own growth —they're focused on a lot of change BUT … that's happening in the market… capital expansion is second.
I seem to be asking a question followed by a question …
- Do we need to brace ourself for more economics and their down trending affect?
- Is this market STILL “bubblicious” my concerns are macroeconomic and valuation
Welcome to my world of defining the “grey’ in our universe!
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.